Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Seeks Input On Standing Up Conformity Assessment Pilot

Executive Summary

In the latest user-fee agreement, FDA and industry agreed to pilot a conformity assessment program where third-party accredited test labs could affirm a manufacturer's conformance to consensus standards, potentially expediting pre-market reviews.

You may also be interested in...

Industry Supports US FDA Conformity Assessment Concept, But Questions Abound

Manufacturers and trade groups generally support an FDA plan to pilot a program that would outsource some standard-conformance certification to outside device testing labs. But companies have questions, and some are urging the agency to consider some standards it currently does not recognize to be included in the pilot.

User-Fee Facts: 10 Key Medtech Details From US FDA Agreements

While Congress makes its push to reauthorize US FDA user fees by mid-summer, here are 10 important details from the underlying industry-agency user-fee agreements that medtech firms should know.

Device Standards Provision In Cures Bill Could Speed Up 510(k) Clearances

Under a provision in the 21st Century Cures bill, which is accelerating towards enactment, FDA may need to consider recognizing more standards, which could speed up review times for 510(k)s. But it is also likely to add a burden for the agency.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts